

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
WO 01/97850 A2

(51) International Patent Classification<sup>7</sup>: A61K 45/06

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
00250194.8 23 June 2000 (23.06.2000) EP  
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: SCHERING AKTIENGESELLSCHAFT  
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: SIEMEISTER, Gerhard [DE/DE]; Reimer-  
swalder Steig 26, 13503 Berlin (DE). HABEREY, Mar-  
tin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). THIER-  
AUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169  
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE  
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular  
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of  
Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

AVAILABLE COPY

**Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their  
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of  
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an  
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1  
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during  
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce  
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also  
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and  
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was  
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4

15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high

20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2

25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing

30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological  
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor  
15 systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

(c) compounds which inhibit activation of intracellular signal pathways of the  
20 receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

(e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents  
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).



Examples for delivery-/Targeting-Systems have been described as ligand/  
antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,  
183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell  
targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A94, 8795-  
5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),  
Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example  
molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R<sub>3</sub> und R<sub>4</sub> a) each independently from each other have the meaning  
of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

wherein the binding is via the two terminal C- atoms, and  
has the meaning of 0 to 4; or

m

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the  
meaning of nitrogen, and each others have the meaning of  
CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

G

20

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  
 $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkeny-  
lene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  
 $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  
 $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

A, B, D, E and T

25

independently from each other have the meaning of N or CH ,  
with the provisio that not more than three of these  
Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or  
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted  
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,  
halogen, alkyl, substituted alkyl, hydroxy, etherificated or  
esterificated hydroxy, nitro, cyano, carboxy, esterificated  
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted  
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,  
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,  
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,  
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if  
15 more than one rest Z is present ( $m \geq 2$ ), the substituents Z are  
equal or different from each other, and wherein the bonds  
marked with an arrow are single or double bonds; or an N-  
oxide of said compound, wherein one or more N-atoms carry  
an oxygen atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive  
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,  
respectively, which results in a prevention of tumor growth and tumor spread, are  
for example

anthranil acid derivatives of general formula IV

30



in which

A


has the meaning of group  $=NR^2$ ,

W


has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group



or A, Z and  $R^1$  together form the group



m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

5

X

Y

p

R<sup>1</sup>

10

15

R<sup>2</sup>

20

R<sup>3</sup>

25

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/ or R<sub>a</sub> and/ or R<sub>b</sub> together with R<sub>c</sub> and or R<sub>d</sub> or R<sub>e</sub> together with R<sub>e</sub> and/ or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

has the meaning of group =NR<sup>9</sup> or =N-,

has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,


has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or

13

C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group




5 R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>

independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




V,

15



in which

R<sup>1</sup> has the meaning of group





20




14



in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,



in which  $R^7$  is  $-CH_3$  or chloro,




in which  $R^8$  is -CH<sub>3</sub>, fluoro,  
chloro or -CF<sub>3</sub>

in which  $R^4$  is fluoro,  
chloro, bromo, -CF<sub>3</sub>,  
-N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or  
-CH<sub>2</sub>OH

in which  $R^6$  is  
-CH<sub>3</sub> or chloro

$R^2$

has the meaning of pyridyl or the group



and

$R^3$

has the meaning of hydrogen or fluoro, as well as their  
isomers and salts can be used as compound I or II in the inventive pharmaceutical  
composition.

These compounds have the same properties as already mentioned above under  
compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in  
combination.

The above mentioned compounds are also claimed matter within the inventive  
combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences  
coding for such peptides, which are used for the treatment of angiogeneous  
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59  
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of  
main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions



a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

- The inventive compositions comprise as compound I or as compound II at least
- 10 one of
- a) compounds which inhibit receptor tyrosine kinase activity,
  - b) compounds which inhibit ligand binding to receptors,
  - c) compounds which inhibit activation of intracellular signal pathways of the receptors,
  - 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
  - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
  - 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
  - f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

25

These compositions are also claimed matter of the present invention.

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites  
5 formation in patients. It is also possible to suppress VEGF oedemas.  
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,  
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as  
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients  
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefore the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, maligneous nephrosclerosis, thrombic microangiopatic syndrome, transplantation rejections  
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, artherosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

## 5    **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

15

20

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.



**Example 2**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in  
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of  
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its  
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000  
 20 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 3**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons  
15 when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>3</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

**Example 4**

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

**Example 5**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-  
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.  
 15 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+



Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>3</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 6**

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-  
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of  
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

### Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the  
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of  
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of  
 20 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of  
 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex  
 via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor  
 system by means of the VEGF receptor tyrosine kinase inhibitor (4-  
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

## CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF  
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I  
10 which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.  
20
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie  
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which  
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,  
b) compounds which inhibit ligand binding to receptors,  
c) compounds which inhibit activation of intracellular signal pathways of the receptors,  
d) compounds which inhibit or activate expression of a ligand or of a  
25 receptor of the VEGF or Tie receptor system,  
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor  
30 systems,  
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.



11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as

25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as

30 compound I and/ or II at least one small molecule of general formula I

41



I,

in which

5

r

has the meaning of 0 to 2,


n

has the meaning of 0 to 2;

R<sub>3</sub> und R<sub>4</sub>

10

- a) each independently from each other have the meaning of lower alkyl,  
 b) together form a bridge of general partial formula II,



II,

15


wherein the binding is via the two terminal C- atoms,  
 and

m

has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T<sub>1</sub> and T<sub>4</sub>;

**G** has the meaning of C<sub>1</sub>-C<sub>6</sub> - alkyl, C<sub>2</sub> - C<sub>6</sub> - alkylene or C<sub>2</sub> - C<sub>6</sub> - alkenylene; or C<sub>2</sub> - C<sub>6</sub> - alkylene or C<sub>3</sub> - C<sub>6</sub> - alkenylene, which are substituted with acyloxy or hydroxy; -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>, oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

**Q** has the meaning of lower alkyl, lower alkyloxy or halogene,

R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or lower alkyl,

**X** has the meaning of imino, oxa or thia:


**Y** has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,  
wherein one or more N-atoms carry an oxygen atom,  
or a salt thereof,

and/or a compound of general formula IV


5



in which

- A has the meaning of group  $=NR^2$ ,
- 10 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,
- Z has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group


15



or A, Z and  $R^1$  together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R <sub>a</sub> , R <sub>b</sub> , R <sub>c</sub> , R <sub>d</sub> , R <sub>e</sub> , R <sub>f</sub>	independently from each other have the meaning of hydrogen, C <sub>1-4</sub> alkyl or the group =NR <sup>10</sup> , and/or R <sub>a</sub> and/or R <sub>b</sub> together with R <sub>c</sub> and/or R <sub>d</sub> or R <sub>c</sub> together with R <sub>e</sub> and/or R <sub>f</sub> form a bound, or up to two of the groups R <sub>a</sub> -R <sub>f</sub> form a bridge with each up to 3 C-atoms with R <sup>1</sup> or R <sup>2</sup> ,
10	X	has the meaning of group =NR <sup>9</sup> or =N-,
	Y	has the meaning of group -(CH <sub>2</sub> ) <sub>p</sub> ,
	p	has the meaning of integer 1-4,
15	R <sup>1</sup>	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C <sub>1-6</sub> -alkyl, or C <sub>1-6</sub> -alkyl or C <sub>1-6</sub> -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R <sup>2</sup>	has the meaning of hydrogen or C <sub>1-6</sub> -alkyl, or form a bridge with up to 3 ring atoms with R <sub>a</sub> -R <sub>f</sub> together with Z or R <sub>1</sub> ,
25	R <sup>3</sup>	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>


substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R<sup>5</sup> and R<sup>6</sup> together form the group



R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>

independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R<sup>1</sup> has the meaning of group

46




in which R<sup>5</sup> is chloro, bromo or the group -OCH<sub>3</sub>,

5



in which R<sup>7</sup> is -CH<sub>3</sub> or chloro,



in which  $R^8$  is  $-CH_3$ , fluoro,  
chloro or  $-CF_3$


in which  $R^4$  is fluoro,  
chloro, bromo,  $-CF_3$ ,  
 $-N=C$ ,  $-CH_3$ ,  $-OCF_3$  or  
 $-CH_2OH$

in which  $R^6$  is  
 $-CH_3$  or chloro

5

$R^2$

has the meaning of pyridyl or the group



10

and

$R^3$

has the meaning of hydrogen or fluoro, as well as their  
isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as  
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-  
yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as  
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium  
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF  
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-  
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-  
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not  
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as  
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium



hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

- 5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
- 10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
- 20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

## Sequence Identifier

5

&lt;110&gt; Schering Aktiengesellschaft

10

&lt;120&gt; Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

&lt;130&gt; 51867AEPMLXX00-P

15

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 59

20

&lt;210&gt; 1

&lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

25

&lt;400&gt; 1

30

```

ttttacagtt ttccttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaa tttttttaa agtcacattc agctcgcttg ctcaaaccag 180
actcccatat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaac gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaacc ccaaacgcga acctaaccac agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatatatt ggcaatttta tattccacag 1260
tcaggtgggt ctgcatagcg tcatttaatg ttaaaccgca tcaggggcct ctctcccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat cgcagtcctg tctggctcgtc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtctcggg ggtacagacc gtgggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggtcttttc tgctgggtgct 1620
cttggacggg cgggtagttc tgctgcagag acaaaagcat tccccttccc ttccgggctg 1680
atthtgggtc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctccttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaa 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

60

&lt;210&gt; 2

&lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 2

5 gttctagatt gttttattca gtaattaget cttaagaccc ctggggcctg tgctacccag 60  
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
 tcaacttact tcctgtggcc cattagggaa gtgggtgacct cgggagctat ttgcctgttg 180  
 agtgcacaca cctggaaaca tactgtcttc attttttcat ccacatcagt gagaaatgag 240  
 10 ttgcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtg gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540  
 cacctcccca tgacatctc catgagcctc ctgatgtagt g

15 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

&lt;400&gt; 3

tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcgg aacctgaatg 120  
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tcctgcgcac tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360  
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataaca 420  
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcat 480  
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 <213> Human

&lt;400&gt; 4

cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60  
 40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180  
 ggggtgcgtc ttggccttgc cgtgcctca tccccggct gaggcagcga cacagcagg 240  
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300  
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcaggggtg 360  
 ctgctggca cacaacacg ggtccatgg tccagccgta caggcgccac tggccataga 420  
 ggaagcctgc ctctagcaca ctcttgca gacactggc gacataggtg cccatcagt 480  
 ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgtcta 540  
 cggccgccag cgccgcctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600  
 ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660  
 50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720  
 aggctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactgcgcgg ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctccctggacc tggccagca 900  
 55 acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960  
 gcacgtcagt gtgtcagcat ggcaccttc tcgttcgccc agcaacaagc ctgcaggag 1020  
 gtctgccacg cccgttctac cgctgcctg ccgggcggcc cagggtggag tggggacgat 1080  
 ggccggagtg acgcccgcg

<210> 5  
 <211> 1015  
 <212> DNA  
 <213> Human

&lt;400&gt; 5

65 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgtct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttgatttt 120  
 agtggggagc ataatagcaa acaccccctt gggttcgcaca tgtacaggaa tgggacccag 180  
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240  
 ccagacccaa gaggagaggg tggtcgcag acaccccggt atgtcagcat cccccgacct 300  
 gccttctgtgc ggcacctccc ggggtgtgtg ttgagtcagc aggcattggg tgagagcctg 360  
 gtatatgtctg ggaacagggt gcagggggcca agcgttcctc cttcagcctt gacttggggc 420  
 atgcaccccc tctccccc aaacaaaacaa gcacttctcc agtatgggtc caggacaggt 480  
 gtcccttcag tctctgtgt atgacctcaa gtccacttg ggccctgcag cccagcctgt 540  
 10 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600  
 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660  
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720  
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780  
 gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840  
 15 accaaaggcc tctgttctg ttatttcact taaatcaaca tgctattttg ttttcaactca 900  
 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgtca cgtgctagtt 960  
 acgtttttct tottacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

&lt;210&gt; 6

&lt;211&gt; 2313

20 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 6

25 ccagagcagg cctgggtgtg agcagggagc gtgcaccgga cggcgggacg gagcaaatgg 60  
 gtctggccat ggagcacgga gggtcctacg ctccggcggg gggcagctct cggggctgct 120  
 ggtattacct gcgtacttct ttccctctcg tctccctcat ccaattcctc atcatcctgg 180  
 ggctcgtgct cttcatgttc tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240  
 30 ccaccgagcg ccgagccgag ggcctataca gtacgtcctc agggctcacg gcctcccagt 300  
 ccaacttgac caaggagctc aacttcacca cccgcgcca ggatgccatc atgcagatgt 360  
 ggctgaatgc tcgccgcgac ctggaccgca tcaatgccag cttccgccag tgccagggtg 420  
 accgggtcat ctacacgaac aatcagaggt acatggtgct catcatcttg agtgagaagc 480  
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcattgctga 540  
 35 atcagaaggt gaagacgtg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600  
 ataaggaaaag cgtgctgctg aacaaacgct tggcggagga acagctgggt gaatgcgtga 660  
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtgca 720  
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780  
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840  
 40 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900  
 ggtggaggag cctggcccga gctcccgccg gcatatcgaa cgcgtggccc gcgagaactc 960  
 agacctccaa cgccagaagc tggaaagccc gcagggcctg cgggcccagtc aggagcgcaa 1020  
 acagaaggtg gagaaggagg ctacggcccg ggaggccaag ctccaagctg aatgtctccg 1080  
 gcagaccagc ctacgcgtgg aggagaaggg ggtgctgcgg aaggaaacgag acaacctggc 1140  
 caaggagctg gaagagaaga agagggaggg ggagcagctc aggatggagc tggccatcag 1200  
 45 aaactcagcc ctggacacct gcatcaagac caagtgcag ccatgatgac cagtgtcaag 1260  
 gcccatgggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagtcca 1320  
 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380  
 ctgaggaggg tccaggcctg aggaccaagg gatggcccga ctccggcggt tgcggaggat 1440  
 gcagggatat gctcacagcg cccgacacaa cccctcccg cggccccaa ccaccaggg 1500  
 50 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcaccccg 1560  
 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620  
 ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680  
 tatagcgatg gcgtcgtgca gatgcagcac gtgcacaca gacatgggga acttggcatg 1740  
 55 acgtcacacc gagatgcagc aacgacgtca cgggccaatgt cgacgtcaca catattaatg 1800  
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagt 1860  
 tcaacacaca ccatgacaac gacacctata gatattggc caacatcaca tgcacgcatg 1920  
 ccctttcaca cacactttct acccaattct cacctagtgt cactgtcccc cgacctggc 1980  
 acacgggcca aggtaccac aggatcccat cccctcccg acagccctgg gccccagca 2040  
 60 ctcccctcct ccagcttcc ggcctcccag ccaacttctc acccccagtg cctggacccg 2100  
 gaggtgagaa caggaagcca ttcacctccg ctcccttgagc gtgagtgttt ccaggacccc 2160  
 ctcggggccc tgagccgggg gtgagggtca cctgtgtgct ggaggggagc cactccttct 2220  
 ccccaactc ccagccctgc ctgtggccgt ttgaaatgtt ggtggcactt aataaatatt 2280  
 agtaaatcct taaaaaaaa aaaaaaaaa aaa

65 &lt;210&gt; 7

&lt;211&gt; 389



<212> DNA  
<213> Human

<400> 7

5

10

```
gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttgttc 360
tccttttgtg gtgtccagtg ggtaacatc
```

<210> 8

15

<211> 157  
<212> DNA  
<213> Human

<400> 8

20

```
tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg
```

25

<210> 9  
<211> 561  
<212> DNA  
<213> Human

30

<400> 9

35

40

```
aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatttc ttttctacct 180
accatattta aattttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgata 480
ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a
```

<210> 10

45

<211> 1508  
<212> DNA  
<213> Human

<400> 10

50

55

60

65

```
cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtec attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactc 240
gagctcaagc caggtgagct taagccactg agcaaggag atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgca cctaccacag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacaac 480
tgtgtgtgaca acccatgttc ttgcagccag tctcactggt gtacacgatg gtcagccatg 540
ggtgtcatgt ccctcttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaactatg 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagctttt 840
gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaata ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtag ttgcaaaact 1020
```



<211> 1002  
 <212> DNA  
 <213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacaggtt gagtagagca acaacaacaa aagccttatgc agtcaccttc 120
tttgaaaatg ttaaatataa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180
10 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa ccaggtttaa ttcccactt ttttaagtag gcttagcttt gagtgatttt 420
tggtataaac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
15 tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaattga gtagtaacca agcttttctg ccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatte 720
attcaataaa cattagccaa gctaagtgtc caagccactg tgccaggat taacaatata 780
20 acaacaataa aagacacagt ccttcctctc aagggtgttc gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatttct 900
gcctatgttc tcagatatte tggttagggtc aggagtggga acccaaaatc aattctttta 960
acaaacacta aaggtgatcc taacacaggc ggtgtgagga cc

```

25 <210> 15  
 <211> 280  
 <212> DNA  
 <213> Human

30 <400> 15

```

cgagggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat taccctatct 60
ataatatttc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
35 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tttttaaaaa tgtagtggtt tgtagtggtt tgtagtggtt 240
caatcttaac tatttccact gcccgggcgg ccgctcgagg

```

40 <210> 16  
 <211> 2041  
 <212> DNA  
 <213> Human

<400> 16

```

45 cccccgcag aactcccccc tggaatagga tttttaaac ccttgacaat tagaaatcct 60
atagagggtta gcattttttta ggtaaaaata tggttgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
50 aattttggtt ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtaacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcaactgagt tggtctcttg aagtataagg gtctaataaa aaataaaaga 660
tagatatttg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaata gagtctgcca actgtattaa atcctctccc 780
acccctccca ccagttgggtc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
60 ccgaaatgaa catgaagcag atgcagcttg gagggccggg gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaatgaag taaatgtcac tctactgtca ttaaataaaa accatttctt 1140
65 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
gtaaatgact ctgggaggat gctaagtcca gagcctcaga ctggtggtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

```

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagttccc	tgaaggcttt	aatttttttag	caagggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgcata	1620
	gtttttctcag	catttttgcag	agaggcacag	ttttcacaat	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttcacc	1740
	tcccggtttc	tgagggtacat	ctttattaac	aagaatcttg	ttagattcgt	tagggacaga	1800
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaag	1860
10	tgagtcacag	atgaaggcag	ctgttgttgg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcatta	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagtctc	120
25	agatactcag	gagactgagc	tggaagggat	cacttgagcc	caagaagttc	aaggttacag	180
	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
35	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
	tcattgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttgggtga	tcacattgtg	caaaatgggt	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcctttt	attaatgagg	agactattgt	300
	gatggcatat	ctcttcacta	tatttaattg	tttccaggga	gtgttcattt	tcattctttca	360
40	ctgtgctctc	caaaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctcg	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatag	tctaccgcta	aatggtaatt	ttacaacacag	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggctg	gagctccatc	1020
	acaaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtcccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggagga	1260
55	gtgagaatga	ggacatttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatggtta	tataatcccc	attaacaaag	1380
	aaggggtgat	tccagaagga	gatgttagag	aaggacaaat	gcagctggtt	acaagctttt	1440
	aatcatacag	ctaaggaatt	ccaagggccca	catgagagta	ttaataaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tgggtgaaaa	aagatgactg	aaccttgcag	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattattttg	tacaaagaaa	agagatgcca	1680
	gccaggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgacgttc	actgcaaatc	ttttacatta	aggcaaagat	tgaacacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatattt	ttctattgct	agggtaaaa	aaatacattt	2100
	gtgtccaact	gaaatataat	tgtcattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattactttac	atttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcacccct	gtttattctt	gaacagaggg	caaaagaggg	actgggcact	tctcacaac	2460
10	tttctagtga	acaaaagggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatatatta	gtaattaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gcccatcact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210>	19					
	<211>	276					
	<212>	DNA					
	<213>	Human					
20	<400>	19					
	ctccctaagt	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtacttttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctccaact	gcatgcctca	agtcctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210>	20					
	<211>	2361					
30	<212>	DNA					
	<213>	Human					
	<400>	20					
35	attgtaccag	ccttgatgaa	cgtgggcctt	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgta	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggat	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaagag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatataatc	cgaaccattg	480
	gaaagttgga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaaagc	cactttgatg	tggagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtggtacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggaagc	840
50	tgccctttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgatagggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
55	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	ccctttacctt	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtag	cggcaggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	accctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
60	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcagg	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccgt	atccgccagg	agatccaaga	gtcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtcact	1740
	tcctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcgga	agtgatgctg	1800
65	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gcccaggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
5	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
	gtccactct	catctaattg	cacagccctc	acaagactaa	agcggaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctctttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctgggtt	c				
10	<210>	21					
	<211>	179					
	<212>	DNA					
	<213>	Human					
15	<400>	21					
	aggtgttaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
20	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210>	22					
	<211>	905					
	<212>	DNA					
	<213>	Human					
25	<400>	22					
	tttttttttt	ttctttaacc	gtgtggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaatgttcc	agtttagaagg	aattcaaacg	gaatgccaa	gtccaagcca	ggctcaagaa	120
30	ataaaaagg	aggtttggag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtggtgggaa	300
	taggggtcatt	aataactatg	aatatatctt	ttagaagggtg	accatttttg	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaa	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcattgcca	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtaa	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaattgcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
	ggcagggtctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
40	cctgaagatg	gtaacccagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
	gttga						
45	<210>	23					
	<211>	2134					
	<212>	DNA					
	<213>	Human					
50	<400>	23					
	ggtctcttct	ttcctttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttta	aagttttttt	120
55	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctt	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
60	agttacttct	ttacatccat	attcccaaa	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggagggtact	aagctcattg	tgtctcctct	agcttttacc	agcatctaatt	gcttcactgc	600
	tttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagtgtg	tttttctcta	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaaaggga	agccattttg	720
	gttattttcac	gttgctgagc	ctttctctca	tgttgaaaca	tctgaagttt	taattctcgg	780
65	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaa	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	cagggtcttag	900

5 taaaaatctca ctttttctcct actttttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttggttttt 1020  
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggcttttatta 1080  
 tgctatatca ctgctcagag gtttaataatc ctactaact atcctatcaa atttgcaact 1140  
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataaatcc cactttactg 1200  
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380  
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440  
 10 ctttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctgggt ctggctggct tcacttcctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680  
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgcccacag 1740  
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860  
 tggacaaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgccatt gttcctggat cccctctggt tccgctggtt cacttcgatg ttggtggctc 1980  
 cagttggaat tgtgatgata tcatgatata caggttttgc actagtaact gatcctgata 2040  
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100  
 agtctatgat gcgatcacia ccagctttta caca

&lt;210&gt; 24

&lt;211&gt; 1626

25 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatatttttg 60  
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120  
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180  
 tatcattttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240  
 agttgttttt tactgatact aaatgtttggc tacctgtgat tttatagtat gcacatgtca 300  
 35 gaaaaaggca agacaaatgg cctctgtgac tgaatacttc ggcaaaacta ttgggtcttc 360  
 attttctgac agacaggatt tgactcaata tttgtagagc ttgctgtaga tggattacat 420  
 ggtagtgtat cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480  
 aatctttttat gtcttttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540  
 aaagctttgt ctaaaaaattt ggcctaggaa tggtaacttc attttcagtt gccaaaggggt 600  
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660  
 atgtattttaa atattttttca tattctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780  
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840  
 tctggaatgc attagttatg ccttgtaacca ttcccagaat ttcaggggca tctgtgggtt 900  
 45 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggctctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 50 cgttgtttct tagggttctt agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320  
 atgccagatg gtgttttatg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 55 attataacct tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560  
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 aaaaaa

&lt;210&gt; 25

60 &lt;211&gt; 1420

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 25

65 gtccagcatt gtttctgctt ctgaaactct tatatagcac tggtttgtaa tcattatgtc 60

5	ttcattgaaa	tccttgctac	ttctotctcct	cctcaatgaa	agacacgaga	gacaagagcg	120
	acacaagcct	aagaaaaacg	agcaaggaag	agtatcttca	ttattctcat	tttctctgag	180
	ttggaacaa	aaacatgaag	gactccaact	agaagacaga	tatttacatt	taaatagatt	240
	agtggaagaa	ctttaagagt	ttccacatat	tagttttcat	tttttgagtc	aagagactgc	300
	tccttgctact	gggagacact	agtagtatat	gtttgtaatg	ttactttaaa	attatctttt	360
10	tattttataa	ggcccataaa	tactgggttaa	actctgttaa	aagtgggcct	tctatcttgg	420
	atgggtttcac	tgccatcagc	catgctgata	tattagaaat	ggcatcccta	tctacttact	480
	ttaatgctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgggtg	540
	tcagccttgc	catgtatcag	tttcacttga	aatttgagac	caattaaatt	tcaactgttt	600
	aggggtggaga	aagaggtact	ggaaaacatg	cagatgagga	tatcttttat	gtgcaacagt	660
15	atccttttgca	tgggaggaga	gttactcttg	aaaggcaggg	agcttaagtg	gacaatgttt	720
	tgtatatagt	tgagaatttt	acgacacttt	taaaaattgt	gtaattgtta	aatgtccagt	780
	tttgctctgt	tttgccctgaa	gttttagtat	ttgttttcta	gggtggacctc	tgaaaaccaa	840
	accagtacct	ggggagggtta	gatgtgtgtt	tcaggccttgg	agtgtatgag	tggttttggct	900
	tgtattttcc	tccagagatt	ttgaacttta	ataattgcgt	gtgtgttttt	ttttttttaa	960
20	gtggctttgt	ttttttttct	caagtaaaat	tgtgaacata	tttcctttat	aggggcaggg	1020
	catgagttag	ggagactgaa	gagtattgta	gactgtacat	gtgccttctt	aatgtgtttc	1080
	tcgacacatt	ttttttcagt	aacttgaaaa	ttcaaaaggg	acatttggtt	aggttactgt	1140
	acatcaatct	atgcataaat	ggcagcttgt	tttcttgagc	cactgtctaa	attttgtttt	1200
	tatagaaatt	ttttatactg	attggttcat	agatggtcag	ttttgtacac	agactgaaca	1260
25	atacagcact	ttgccaaaaa	tgagtgtagc	attgtttaaa	cattgtgtgt	taacacctgt	1320
	tctttgtaat	tgggttgtgg	tgcattttgc	actacctgga	gttacagttt	tcaatctgtc	1380
	agtaaataaa	gtgtccttta	acttcaaaaa	aaaaaaaaaa			
	<210> 26						
	<211> 689						
30	<212> DNA						
	<213> Human						
	<400> 26						
35	aaacaaacaa	aaaaaaagtt	agtactgtat	atgtaaatac	tagcttttca	atgtgctata	60
	caacaaatta	tagcacatcc	ttcctttttac	tctgtctcac	ctccttttagg	tgagtacttc	120
	cttaaataag	tgctaaacat	acatatacgg	aacttgaaag	ctttgggttag	ccttgcccta	180
	ggtaatcagc	ctagttttaca	ctgtttccag	ggagttagtg	aattactata	aaccattagc	240
	cacttgtctc	tgcaaccattt	atcacaccag	gacagggctc	ctcaacctgg	gcgtactgtg	300
40	catttggggc	caggtgattc	ttccttgcaa	gggctgtcct	gtacctgccc	gggaggccgc	360
	tcgaagcgtg	gtcgcggccg	aggtactgaa	aggaccaagg	agctctggct	gccctcagga	420
	attccaaatg	accgaaggaa	caaagcttca	gggctctggg	tggtgtctcc	cactattcag	480
	gaggtggctg	gaggtaacgc	agcttcattt	cgctccagtc	tttccagtat	ttaaagtgtg	540
	tgtcaagatg	ctgcattaaa	tcaggcaggt	ctacaaaggc	atcccaagca	tcaaacatgt	600
45	ctgtgatgaa	gtaatcaatg	aaacaccgga	acctccgacc	acctcctgaa	tagtgggaga	660
	cacacccaga	gcctgaagtt	tgctccttgc				
	<210> 27						
	<211> 471						
	<212> DNA						
50	<213> Human						
	<400> 27						
55	tcccagcggc	atgaagtttg	agattggcca	ggccctgtac	ctgggcttca	tctccttcgt	60
	ccctctcgtc	cattgggtggc	accctgcttt	gcctgtcctg	ccaggacgag	gcaccctaca	120
	agccctaacc	caggccccgc	ccagggccac	cacgaccact	gcaaacaccg	cacctgccta	180
	ccagccacca	gctgcctaca	aagacaatcg	ggccccctca	gtgacctcgg	ccaccacagc	240
	gggtacaggc	tgaacgacta	cggtgtgagtc	cccacagcct	gcttctcccc	tgggctgctg	300
60	tgggctgggt	cccggcgggg	ctgtcaatgg	aggcaggggt	tccagcacia	agtttacttc	360
	tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgtctt	tagagcacag	420
	ggacagaggg	ggaaataaga	ggaggagaaa	gctctctata	ccaaagactg	a	
	<210> 28						
	<211> 929						
65	<212> DNA						
	<213> Human						
	<400> 28						



	ggtgaactca	gtgcattggg	ccaatggttc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acggttttgg	tgctgggtgg	ctttccctc	actgtcattg	gaggcatctt	120
	tggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
5	gattccaccc	cagccctggt	acaagtctac	tgcatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tggagctgta	ctacatcttt	gccacagtat	ggggctcgga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgcactca	cctacttcca	gttgtctggg	gaggattacc	gctgggtggg	420
	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcata	ttcctctact	cagttttcta	480
10	ttatgcccgg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttcctcat	gctgggcacc	atctcctttt	ttctctccct	600
	aaagtccatc	cggatatatct	atgttaacct	caagatggac	tgagtctctg	atggcagaac	660
	tattgctgtt	ctctcccttt	cttcacgtcc	gttgaactc	tcctaccagc	ttctctctcg	720
	attgactgaa	ttgtgtgatg	gcattgttgc	cttccctttt	tccttttggg	cattccttcc	780
15	ccagagaggg	cctggaaatt	ataaatctct	atcacataag	gattatatat	ttgaactttt	840
	taagttgcct	ttagttttgg	tcctgatttt	tctttttaca	attaccaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
	<210> 29						
20	<211> 1775						
	<212> DNA						
	<213> Human						
	<400> 29						
25							
	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaatgt	ccgaagggat	tttggccaac	60
	accagaaaaa	gccaatgtcc	taggaattcc	ctcccaaaa	gcttcccaaa	aaattactca	120
	ttgacaattc	aaattgcaat	tggttgccgg	cagccccggc	ggccttcagt	ccgtgtgggg	180
	cgcccgcggtg	gccttctcct	cgtaggactc	cccaactcgc	ttcactctgc	gtttatccac	240
30	aggataaaag	caccgctggg	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccgggtga	gacgtgggca	tggtgatgat	gaaggcaaag	acgtcatcaa	tgaaggtgtt	360
	gaaagccttg	taggtgaagg	ccttcacagg	cagatgtgcc	actgacttca	acttgtagtt	420
	cacaaagagc	tggggcagca	tgaagaggaa	accaaaggca	tagaccccg	tgacgaagct	480
	gttgattaac	caggagtacc	agctcttata	tttgatattc	aggagtgaat	agacagcacc	540
35	cccagacacg	agaggtatca	gcaggtatga	caagtacttc	atggcctgag	tatcgactc	600
	ctcgggttttc	ctctcagatt	cgctgtaagt	gccaaactga	aattcgggca	tcaggcctct	660
	ccaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggctccaac	720
	accgcgcggg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
	cacgggtgctg	aagcagcgcc	agagcactgc	cttggtggac	atgccgatca	tgctcttctt	840
40	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaa	aaggtcagcg	ccaggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaacccgaa	ctgctgcagg	gagtacacgg	cgctcctgcat	1020
	gtggatccag	aagcgagcc	gccccagtga	gaccttgcg	taggacacgg	tgaggggcag	1080
	ctcgggtggg	gagcggttta	tgaccatcag	gtccttcacg	cggttgctga	gctgggtcat	1140
45	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcgcca	ggcaggagg	acccgtcaaa	gacaaagtgt	tcgccatca	cgttcagcgc	1260
	cagcccggtg	cgccagtggg	acactggctc	atccagggca	ctcgtcggct	tcttctccgc	1320
	ctcgatctgc	tgtgtatcag	actccccggt	gagcaggttg	atttcttctg	gcttggggac	1380
	catgtaggtg	gtcagaggac	tgaccagggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
50	cccagcgtga	tggaggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttcttttg	1500
	tacagaaaaca	ttaactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccaggtcg	atgttgttct	cagcacccag	gtgggacctc	gtcgtgggtg	acacgtcag	1620
	ctgcagcttg	ggccgcccgc	ccaggtaggg	ctggatgcag	ttggcgctgc	cggagcacgg	1680
	gcgggtgtag	acgatgccgt	acatgaccca	gcaggtgtgc	accacgtaga	ccacgaacac	1740
55	gcccaccacc	aagctggtga	aggagctgcg	gcccc			
	<210> 30						
	<211> 1546						
	<212> DNA						
60	<213> Human						
	<400> 30						
	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgctaatt	60
65	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgacca	ttctttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacacaaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaca	540
	acagaaaatac	caggtagtgt	tctacaacca	gatgcatac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaaagtc	ctgcagaatc	1020
	aatcccgaact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaattttag	1200
	gaggagaatt	tgtagcagtg	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
20	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggtcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacataata	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
35	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatcctgggc	180
	cccactaaag	cagaacgtta	cggatatttc	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaatac	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagtataac	480
	ttttaatagc	ttcctcagca	cactattttc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccatc	ggctctgtaa	aaaggaagtc	tgaatacaga	gcccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatcatcaa	cacagacacg	atttggactc	cctgacaggt	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgtcac	caccgtcccc				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
55	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcttttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
60	atgttctggg	ttttttcctt	cttttttaga	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcaactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tcacataattt	tcacacaata	acagtccttt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccttc	cccttggttt	tcaagtatct	660
65	tgaggttggtg	cacaaaaatt	aggtcatgcc	ttcagtgctt	tggtctttta	acctaccctt	720
	tgacaatcag	gtgctaataga	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaactc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtccttttga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactct	tgcaaaactc	gatgatacct	gcttatgtgg	1200
	attccttttc	acactgcttt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
10	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
	atttaaacia	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagttattg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaat	gtgtaactta	agggtattat	atatataaat	1560
15	acatatatac	ctttgttaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagttaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtagcgatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttggagccc	660
35	cagacaattc	agtcctcaaa	ccttctcaaa	gtcccttcat	tgcttgactc	720	
	aataagattg	atagggtata	tgatttgaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtacc	tacctctgca	catactgggt	atggcatggg	aagtctgatc	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaaagt	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctcctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattccttga	1260
45	aaagacctgg	agaaaacatt	ggctgggtta	ccctcctctg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	attttttagtg	cagaaattat	ttatcaattt	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgga	1800
	gcaggtcagg	tgaacacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgtagacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atggtgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaaataga	acctatccct	ggtagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatatctc	tgtagtaag	atgacccggc	agtcatttga	tgactcaaaa	2040
	gactgggtta	gagatgaaat	gcagaagagt	gactggcagc	ttattgttga	gctgaagaaa	2100
	gtatttgaaa	tcatctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tggttttaag	tttgcccttc	2400
	cccaaatttg	gattttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700  
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaaacaga 2760  
 catccaccag taagcaagct ctgttaggct tccatggtta gtggtagctt ctctcccaca 2820  
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880  
 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940  
 tgatcggttt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

20 acggggcgcc ggacgaccgc cacatcttat cctccacgcc ccactcgcac tccgagcggg 60  
 accgccccgc actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120  
 cggcttgagc cgagcgcagc accccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180  
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240  
 ggaactcccc cggcccaagg ctcggtgggt cggggtcgcg cggccgcaga aggggcccggg 300  
 tccgccccgc aggggaggcg cccccgggga cccgagaggg ggggtaggagc cgcgggctgc 360  
 tgggtcgggc gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccc 420  
 25 tgtgcgagga ggaggcgcg gcggcgcgagg aggatgtact tgggtggcggg ggacaggggg 480  
 ttggccgggt gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540  
 tccggcaccc gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600  
 aaccgcccgc ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgcagccag 660  
 gggaaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgctg 720  
 30 tgtgtcatcc gcccccgct caatggcgac tcctcaccg agtacgaagc gggcgtttgc 780  
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840  
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900  
 aatccctttg agtttccaag tcaggatatg tgcttttcag ctttaaagag aattgaagaa 960  
 35 gagaagccag attgctccaa ggcccgtgtg gaagtccagt tctctccacg ttgtcctgaa 1020  
 gattctgttc tgatcgagg ttatgtcct cctggggagt gctgtccctt accgagcgc 1080  
 tgctgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140  
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200  
 gttttcggcg tggactgcag gactgtggaa tgcctactg ttcagcagac cgcgtgtccc 1260  
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaa 1320  
 agatgcaggt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380  
 cgcatagtct ctogtggcga tgggacacct ggaagtgtgt gtgatgtctt tgaatgtgtt 1440  
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500  
 cgaatggaca actgtcggtt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560  
 45 cagtgtggtg agataaactg cgagaggtac tacgtgcccg aaggagagtg ctgccagtg 1620  
 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgccaa tggcctgatc 1680  
 cttgccccag gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740  
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800  
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860  
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920  
 cacaatggtt gtccgacctg tcagtgcata aacaccaggg aactatgttc agaacgtaaa 1980  
 caaggctgca ccttgaactg tcccttcggt ttccctactg atgccccaaa ctgtgagatc 2040  
 tgtgagtgcc gcccgaaggc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100  
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160  
 55 ctctcatgca gtaagatctg cccttgggt ttccagcagg acagtcacgg ctgtcttate 2220  
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtcggg cacttgtctc 2280  
 accgtggatg gtcatcatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340  
 tactgtctca atgtgtgccc atgtgtgccc gcccgtgccc tgccctgtgc 2400  
 aacccacca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460  
 60 aagccagagc tcagtactcc ctccatttgc cacgcccctg gaggagaata ctttgtggaa 2520  
 ggagaaacgt ggaacattga ctccgtgact cagtgcacct gccacagcgg acgggtgctg 2580  
 tgtgagacag aggtgtgccc accgctgtct tgccagaacc cctcacgcac ccaggattcc 2640  
 tgtgcccac agtgtacaga tcaacctttt cggccttcc tgtcccga taacagcga 2700  
 cctaattact gcaaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760  
 65 gacgtttgta ccagctgcat ctgcattgat agcgtaatga gctgtttctc tgagtcctgc 2820  
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgttcc ctactgcata 2880  
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgacgggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgcccgtg	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagaggttga	cctggaggtt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgctccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctta	ttataatagc	attcctatct	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccaggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggtctctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaaat	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
15	atgtgcagaa	caagcattcc	cacttttctt	caagataact	gaccaagtgt	tttcttagaa	3780
	ccaaagtgtt	taaagtgtgt	aagatatatt	tgctgtgaag	atagctgtag	agatatttgg	3840
	ggtggggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctggttgctg	caaagctcag	gcctgaatga	4020
20	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
	agcacatcag	aaccttttga	cagccatccc	aggctctaaag	ccacaagtgt	cttttctata	4140
	cagtcacaac	tgtagtaggc	agtgaaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
25	atgtgagcac	tgtagctttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tctttattat	atactgattc	tacaaaaatg	aaactacttc	4560
	attttaattg	tatatatttc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
30	aaacttttag	aattatagga	gtattttatg	aactatctta	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatatata	atacatatat	atttatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
35	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attcctttat	taaaatcttc	ctcattttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatcact	aatcagctcc	tggtattttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataataac	tgactgtata	ctatagtggg	aacttttcaa	5220
40	acagccctta	gcacttttat	actaatatac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
	tgcttggttg	gaaagacaca	gataccaggt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaataacttg	acagaggttg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaggaa	5520
45	aaaaagattt	attatcaagg	ggcaatatatt	ttatcttttc	caaaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	ttgttttttt	5700
	caatcatggc	catattatga	aaatactaac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	ttatctctga	gtgctgtatc	tattactctt	ttactttggg	5820
50	tctgttgtg	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaat	agatatatgg	5880
	cacttgaggt	gcacataggt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpgsivqgvc	60
65	gccytcasgg	nescggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtdqll	120
	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpge	240

5 ccdlyeckpv fgvdertvec ptvqqqtacpp dsyetqvrlt adgcctlptr ceclsglclcgf 300  
 pvcevgstpr ivsrgdgtpp kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrcq 360  
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420  
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsnctltrk 480  
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540  
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kreasasag 600  
 ppilsgtclt vdghhhknee shwdgcrecy clngremcal itcpvpacgn ptihpgqccp 660  
 scaddfvvqk pelstpsich apggeyfvag etwnidsctq ctchsgrvlc etevcppllc 720  
 10 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780  
 viscfesesc svscerpvlr kgqccpycik dtipkvvch fsgkayadee rwdldscstc 840  
 yclqggtlcs tvscpplpcv epinvegscc pmcpemyvpe ptnipiekt n hrgevdlevp 900  
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960  
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgrtrvqd ssqrmrliae pdarfsgfys 1020  
 15 mqkqnhlqad nfyqtv

&lt;210&gt; 35

&lt;211&gt; 716

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 35

25 gcagtagctg gagtgctctg caggggggaaa gcgaaccggg ccctgaagtc cgggggcagtc 60  
 acccggggct cctggggcgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120  
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240  
 30 ccagaactcg gtcctatctt acagattgag aaactatggt tcaagaagag aggacggggc 300  
 ttgagggaat ctcttgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360  
 aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420  
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480  
 ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 tctggttagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600  
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

&lt;210&gt; 36

&lt;211&gt; 395

&lt;212&gt; DNA

40 &lt;213&gt; Human

&lt;400&gt; 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc caccctaaa atacttcaga ggctgaaaaa 180  
 atgattatta cattggaatc cttagccta tgtgatattt cttaacttt gcactttcac 240  
 gccagtaaa accaaagtca gggtaaacca tgtcatttta caaatgtta aaacccta 300  
 50 tgcagttcct tttttaaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 agaagcaagg aaagcattct taattctacc atcct

&lt;210&gt; 37

&lt;211&gt; 134

&lt;212&gt; DNA

55 &lt;213&gt; Human

&lt;400&gt; 37

60 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gagtctccat 120  
 aagggaacac gtgt

&lt;210&gt; 38

&lt;211&gt; 644

&lt;212&gt; DNA

65

&lt;213&gt; Human

&lt;400&gt; 38

```

5  aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
   cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
   ggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
   ggaatatgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
   gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10  ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
   aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
   ttgcgaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
   caagagggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
   tcaaaggctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
15  gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

```

&lt;210&gt; 39

&lt;211&gt; 657

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 39

```

25  ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
   gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
   agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
30  tggctcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
35  atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

```

&lt;210&gt; 40

&lt;211&gt; 1328

&lt;212&gt; DNA

40 &lt;213&gt; Human

&lt;400&gt; 40

```

45  acaattttta aataactagc aattaatcac agcatatcag gaaaaagtag acagtgagtt 60
   ctggttagtt tttgtaggct cattatgggt agggctggtt agatgtatat aagaacctac 120
   ctatcatgtc gtagtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180
   gctaataatg atccttttaa gcaactctca ggaacaaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attccccaaa ttttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
50  acttctttca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420
   taagattcac tatatgtgat agtatgatat gcattttattt aaaatgcatt agactctctt 480
   ccatccatca aatactttac aggatggcat ttaatacaga ttttctgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaac 600
   tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
   actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaattat 720
55  aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840
   tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
   attggattga catatgggtt gccagcctat ggggtttacag gcattgccc  aacatttctt 960
   tgagatctat atttataagc agccatggaa ttctatttat gggatgttgg caatcttaca 1020
60  ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
   gtgagtttaag ctatggttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
   tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
65  ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
   tgaaaaaa

```

<210> 41  
 <211> 987  
 <212> DNA  
 <213> Human

5

<400> 41

10	aacagagact	ggcacaggac	ctcttcattg	caggaagatg	gtagtgtagg	caggtaacat	60
	tgagctcttt	tcaaaaaagg	agagctcttc	ttcaagataa	ggaagtggta	gttatggtgg	120
	taaccccccg	ctatcagtcc	ggatggttgc	caccctcct	gctgtaggat	ggaagcagcc	180
	atggagtggtg	agggaggcgc	aataagacac	ccctccacag	agcttgcat	catgggaagc	240
	tggttctacc	tcttcctggc	tcctttgttt	aaaggcctgg	ctgggagcct	tccttttggg	300
	tgtctttctc	ttctccaacc	aacagaaaag	actgctcttc	aaagggtggag	ggtcttcacg	360
15	aaacacagct	gccaggagcc	caggcacagg	gctgggggcc	tggaaaaagg	agggcacaca	420
	ggaggaggga	ggagctggta	gggagatgct	ggctttacct	aaggtctcga	aacaaggagg	480
	gcagaatagg	cagaggcctc	tccgtcccag	gcccattttt	gacagatggc	gggacggaaa	540
	tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtg	tggccgggtg	600
	gaacaagcac	aggccttgga	atccaatgga	ctgaatcaga	accctaggcc	tgccatctgt	660
20	cagccgggtg	acctgggtca	attttagcct	ctaaaaagcct	cagtctcctt	atctgcaaaa	720
	tgaggcctgt	gatacctgtt	ttgaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
	aatagtctac	ggcatacca	ccctgaacgt	gcctaatctc	gtaagctaag	cagggtcagg	840
	cctgggttagt	acctggatgg	ggagagtatg	gaaaacatac	ctgcccgcag	ttggagttgg	900
	actctgtctt	aacagtagcg	tggcacacag	aaggcactca	gtaaataactt	gttgaataaa	960
25	tgaagtagcg	atttggtgtg	aaaaaaa				

<210> 42  
 <211> 956  
 <212> DNA  
 <213> Human

30

<400> 42

35	cggacgggtg	ggcggacgcg	tgggtgcagg	agcagggcgg	ctgccgactg	ccccaaccaa	60
	ggaaggagcc	cctgagtcgg	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
	ttgcctgtct	aaagccttaa	ctaagactcc	cgccccgggc	tggccctgtg	cagaccttac	180
	tcagggggatg	tttacctggt	gctcgggaag	ggaggggaag	gggccgggga	gggggcacgg	240
	caggcgtgtg	gcagccacac	gcaggcggcc	agggcgcca	gggacccaaa	gcaggatgac	300
	cacgcacctc	cacgccactg	cctccccoga	atgcatttgg	aaccaaaagtc	taaactgagc	360
40	tcgcagcccc	cgcgcctcc	ctccgcctcc	catcccgctt	agcgcctctg	acagatggac	420
	gcaggccctg	tccagcccc	agtgcgctcg	ttccggctcc	cacagactgc	cccagccaac	480
	gagattgctg	gaaaccaagt	caggccaggt	gggcggacaa	aagggccagg	tgcggcctgg	540
	ggggaacgga	tgctccgagg	actggactgt	ttttttcaca	catcgttgcc	gcagcgggtg	600
	gaaggaaagg	cagatgtaaa	tgatgtgttg	gtttacaggg	tatatttttg	ataccttcaa	660
45	tgaattaatt	cagatgtttt	acgcaaggaa	ggacttacc	agtattactg	ctgctgtgct	720
	tttgatctct	gcttacggtt	caagaggcgt	gtgcaggccg	acagtcggtg	accccatcac	780
	tcgcaggacc	aaggggggcg	ggactgctgg	ctcacgcccc	gctgtgtcct	ccctcccctc	840
	ccttccttgg	gcagaatgaa	ttcgatgcgt	attctgtggc	cgccatctgc	gcagggtggt	900
	ggtattctgt	catttacaca	cgtcgttcta	attaaaaagc	gaattatact	ccaaaa	

50 <210> 43  
 <211> 536  
 <212> DNA  
 <213> Human

55 <400> 43

60	aaataaacac	ttccataaca	ttttgttttc	gaagtctatt	aatgcaatcc	cacttttttc	60
	cccctagttt	ctaaatgtta	aagagagggg	aaaaaaggct	caggatagtt	ttcacctcac	120
	agtgttagct	gtcttttatt	ttactcttgg	aaatagagac	tccattaggg	ttttgacatt	180
	ttgggaaccc	agttttacca	ttgtgtcagt	aaaacaataa	gatagtttga	gagcatatga	240
	tctaaataaa	gacatttgaa	gggttagttt	gaattctaaa	agtaggtaat	agccaaatag	300
	cattctcatc	ccttaacaga	caaaaactta	tttgtcaaaa	gaattagaaa	aggtgaaaat	360
	atTTTTTcca	gatgaaactt	gtgccacttc	caattgacta	atgaaataca	aggagacaga	420
65	ctggaaaaag	tgggttatgc	cacctttaaa	accctttctg	gtaaatatta	tggtagctaa	480
	aggggtggtt	ccccggcacc	tggacctgga	caggtagggg	tccgtggtta	accagt	



<210> 44  
 <211> 1630  
 <212> DNA  
 <213> Human

5

<400> 44

```

10  ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
    gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
    tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtccact 180
    atccccctcg gaggggaagag gcaggaaaat tctcccggg tccctgtcat gctactttct 240
    ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
    gtgatttccc ttaggccag gacttgggcc tccagctcat ctgttccttc tggggccatt 360
    catggcaggt tctgggctca aagctgaact ggaggagaa gagatacaga gctaccatgt 420
15  gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
    tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
    gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
    attaggaagt cgggggtggg tgggtgggtg gggctagtgt gggttgaatt taggggccga 660
    tgagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtcccct 720
20  ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatctcg tgcccagaaa 780
    agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgccctgg 840
    gcccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtgg 900
    tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
    agtttggctg gtagagcctt ctagaggttc agaatttagg cttcaggatc agctgggggt 1020
25  atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
    tgaggggacag tttgggtttg ggacttacca gggatgatgt agatctggaa cccccaagt 1140
    aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
    aaagagtgac cttagagggc tccttggggc tcagggaatgc tcctgctgct gtgaagatga 1260
    gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
30  ctgggtccct tgtagcacag gagactgggg ctaagggccc ctcccaggga agggacacca 1380
    tcaggcctct ggctgaggca gtatcataga ggatccattt ctacctgcat ttcccaggg 1440
    actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
    cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
    cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620
35  caaaaaaaaaa
  
```

<210> 45  
 <211> 169  
 <212> DNA  
 <213> Human

40

<400> 45

```

45  tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
    taaaactggg ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120
    ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagttga
  
```

<210> 46  
 <211> 769  
 <212> DNA  
 <213> Human

50

<400> 46

```

55  tgcaggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60
    atttgcgct ttcacttttt ataaagtgtc acataaaaat tcataatttc aaatttaaaa 120
    acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
    aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240
    aaggtgtact aggcaatctt agagatctgg caacttattt tataataaag gcatctgtga 300
    ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
    cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
    ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
    catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
    tattttgtaa taaaatcaaa tttccattg aaaccttcaa aaactttgca gaatgaggtt 600
    ttgatataat gtgacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
    cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720
  
```

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47  
<211> 2529  
<212> DNA  
<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60  
gtgaaaatta gtgactggtt aaggtgtgac actgtacata tcatcatttt ctgactgggg 120  
tcaggacctg gtcctagtc acaagggttg caggaggagg gtggaggcta agaacacaga 180  
aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240  
ggatggtggg aagggggctc cctggtgggg ccgagccagg agtcccaagt cagctctcct 300  
15 gccttactta gctcctggca gaggtgagtg ggggacctac gaggttcaaa atcaaattggc 360  
atgttgccag cctggcctta ctaacagggtt ccagagtgct ctctgttggt tgagctctcc 420  
tggtgctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480  
attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcc ctctccctcc 540  
actagtgggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600  
20 ccagaggccc ctgcaacttt gcggatttcc agaagggtgat aaaaagagca ctcttgagt 660  
ggtgccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttctac 720  
caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780  
tgaactctgg tgttgacagg tacaaggagg aagagatggg gactgtgaag aggggagggc 840  
ttccctcatc ttcccaaga tcttggtttc cataaactat gcagtcataa ttgagaaaaa 900  
25 gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtgt 960  
ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020  
ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080  
aggtgaacag tcctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140  
ttatgaaact gaaaaataa tcaagggtatt gggaagaata atttcccctc gattccacag 1200  
30 gagggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260  
acaaatcatc aggggttgcc tggctggcag tcacatgctt ccctggtttt agcacacata 1320  
caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380  
ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcac 1440  
gcagtggggc tgacctgaca aagccccag tttcctgttg caggttctgg gagaggatgc 1500  
35 attcaagctt ctgcagccta ggggacagg ctgctgttcc agttattact gcctcgagc 1560  
tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620  
cttcggcagt attctcggtt gtatgttctc tggcagagag aggcagatga acatagtttt 1680  
agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740  
tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800  
40 ccagagccaa taaaagatct ttgagctctt ggtgaattca cgaagtgacc ccagctttag 1860  
ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920  
gggggagtg gagggggaag aaagagaaca gagcggcact gggatttgaa aggggaacct 1980  
ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040  
tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100  
45 tgaaattata ctctgacagt ttctctcttc ctgcctcttc cctctgcaga gtcaggacct 2160  
gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaag 2220  
gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggct 2280  
tcgagtcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340  
ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400  
50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460  
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520  
ggggtgtcc

<210> 48  
<211> 1553  
<212> DNA  
<213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60  
ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120  
aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaaagt 180  
ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240  
65 ggggccttga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatccca 300  
tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

	ccatcaagag	ggctatggga	gccaagtga	cacgggggat	tgaggcta	tcacctga	420
	tcgaaaacag	cgcccagctt	cctcaccgca	ggcacgcgtc	ttttcttttt	ttttcctcga	480
	gacggagtct	cgctgtgttg	cccaggctgg	agtgcagtgg	cacggctctcg	gctcactgca	540
	agctccacct	cctggattca	taccattctc	ctgcttcagc	cttccgagta	gctgggacta	600
5	taggtgccaa	ccactacgcc	tagctaattt	ttttttgtat	tttttagtaga	gacaggggtt	660
	caccgtgtta	gccaggatgg	tctcgtcctg	actttgtgat	ccgcccgcct	cggcctccca	720
	aagtgtctgg	attacaggcg	tgagccacca	cacttgcccc	cggcacgtat	cttttaagga	780
	atgacaccag	ttcctggctt	ctgaccaaag	aaaaaatgtc	acaggagact	ttgaagaggg	840
	agacaggagg	gtggtggcag	caacactgca	gctgcttctg	gatgctgctg	gggtgctctc	900
10	cggagcgggt	gtgaacagcg	cacttcaaca	tgagcaggcg	cctggctccg	gtgtgtcctc	960
	acttcagtgg	tgacactgga	tggtggaagc	cagcctttgg	ggcaggaaac	cagctcagag	1020
	aggctaccca	gctcagctgc	tggcaggagc	caggatatta	cagccataat	gtgtgtaaag	1080
	aaaaaacacg	ttctgcaaga	aactctccta	cccgtcggg	agactggggc	tccttgcttg	1140
	ggatgagctt	cactcaacgt	ggagatggtg	gtggactggt	ccctgaaaag	cgggctcttg	1200
15	agggccaagt	gaggtcctca	ggcctaac	ccagtggccc	tctgaaaggg	ggtgtgcagg	1260
	cgaggggagc	aggaggcttc	tctctagtcc	ctttggaggc	tttggctgag	agaagagtga	1320
	gcagggagct	gggaatggtc	caggcaggga	agggagctga	agtgattcgg	ggctaattgc	1380
	tcagatcgat	gtatttctct	ccctggctct	cggagccct	cttgtcaccg	ctgctgccct	1440
	gcagggagcc	catctcttct	gggagcttat	ctgacttaac	ttcaactaca	agttcgctct	1500
20	tacgagaccg	ggggtagcgt	gatctcctgc	ttccctgagc	gcctgcacgg	cag	
	<210>	49					
	<211>	921					
	<212>	DNA					
25	<213>	Human					
	<400>	49					
	ctgtggctcc	agctactcag	gaggctgagg	cgggaggatt	gcttgagccc	aggagttgga	60
30	tggtgcagtg	agccaagatc	gcaccattgc	cctccactct	gggccacgga	gcaataccct	120
	gtctcagaaa	acaaacaaca	aaaagcagaa	acgctgaagg	ggtcgggtta	cgggaaaacc	180
	gctgtgcaga	acacttggct	actcctacc	cagatcagtg	gacctgggaa	tgaggggttg	240
	tcccgggagg	cttttctcca	agctgttgcc	accagaccgc	ccatgggaac	cctggccaca	300
	gaagcctccc	ggggagttag	ccagagcctg	gaccgctgtg	ctgatgtgtc	tgggggtggag	360
35	ggaggggtgg	gagtgtgcaa	gggtgtgtgt	gtgcccgggg	ggtgttcag	ggcaagcatg	420
	tgcgtgcctg	tgtgtgtgag	tgccccctcc	ctgcagccgt	cgggtggtatc	ttccctccagc	480
	cccttcgcca	ccttctgagc	attgtctgtc	cacgtgagac	tgcccagaga	cagcagagct	540
	ccacgtgggt	ttaaggggag	acctttccct	ggacctgggg	gtctcgccgt	atctcatgac	600
	caggtgctaa	atgacccgac	atgcatcacc	tgcctttcga	tgaccaacct	ccctgtcccc	660
40	gtcccgtgta	cctgcccccg	tgccgtctca	cggtagtgc	tgtcctgac	attgggtgtc	720
	actgtagcaa	actacattct	ggatgggaat	ttcatgtac	atgtgtggca	tgtggaaaat	780
	ttcaaataaa	atggacttga	tttagaaagc	caaaaagctg	tgtggctcct	ccagcacgga	840
	tactttgacc	tcttgccctac	aacccttcc	ttgggtccga	ggctggtagc	tttgttccact	900
45	tcagatgggt	gggggcgggt	g				
	<210>	50					
	<211>	338					
	<212>	DNA					
	<213>	Human					
50	<400>	50					
	atgatctatc	tagatgccct	accgtaaaat	caaaacacaa	aaccctactg	actcattccc	60
55	tcccttccag	atattacccc	atttctctac	ttcccattgt	agccaaactt	tccaaaaatt	120
	catgttctgt	cttcatttcc	tcattgtcaa	cccaccctgt	cttagctacc	acccctcagt	180
	aacgacctag	cctgggtaga	aacaaatgtc	agcatgatac	catactcaat	gacccctcgt	240
	cactgttgct	attgtcatca	ttccatggcc	ttactttccc	tctcagcgcc	atttgcatac	300
	gtaagaaact	ttctttcttg	aattcttggt	tctcttgg			
60	<210>	51					
	<211>	1191					
	<212>	DNA					
	<213>	Human					
65	<400>	51					

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggttggtct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
	gcacattaca	acaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
5	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcgga	gacgctcctg	acaagtcggg	360
	aatttctcta	tttctccact	ggtgcaaaga	gcggatttct	ccctgcttct	cttctgtcac	420
	ccccgtcct	ctccccagg	aggctccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
10	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggttcttag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaata	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
15	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaattaaaa	gttgaaaaag	acttgaagac	tggagaaagt	acagttctgt	1080
	cttccaatac	ctctggccat	cagatgacct	taaaagggtac	aggagtataa	gtttaagatg	1140
20	atggggcaaaa	gtccagtgta	ttcagtaaa	tgctaatacac	aagttggagg	t	
	<210>	52					
	<211>	1200					
	<212>	DNA					
25	<213>	Human					
	<400>	52					
	aacagggact	ctcactctat	caaccccagg	ctggagtccg	gtgcgcccac	cctggctccc	60
30	tgcaacctcc	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	ttttttaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggttgg	tttaaaaata	attgcttttt	tattattttt	gcatttttgc	300
	accaacctta	atgctatgta	aatagttgtt	atactgttgc	ttaacaacag	tatgacaatt	360
35	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggtggct	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagttatgg	tacagtggaa	agagttagtg	aaaacataaa	catttggaac	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
40	tgctactaat	tagtataaat	ctttgcacaa	attacatcac	ctttgagctc	cagttgcctc	720
	acctgtaaaa	tgaagaact	ggatactctc	taaggtcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaattgct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatcct	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
45	agagatgggg	tctcactctg	tcaccagac	tggagtacag	tggcacaatc	atagctcact	1020
	gtgcctcaa	attcatgggc	tcaagtgate	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatcct	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	acttattttg	1200
50	<210>	53					
	<211>	989					
	<212>	DNA					
	<213>	Human					
55	<400>	53					
	aagccaccac	tcaaaacttc	ctatacat	tcacagcaga	gacaagtga	catttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
60	gattcaatta	gtccttgggc	tggtcgactg	tgcaggagtc	caggagacct	ctacaaatgc	180
	agagtgactc	tttaccacaa	taaaccctag	atacatgcaa	aaagcaggac	ccttcctcca	240
	ggaatgtgoc	atttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaa	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcaatg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
65	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttggtcaggc	ggtctcgaa	540
	cccaacctca	gtgatctg	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

5	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttcaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttaatatatt	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggtcca	ccgcaatctc	tgccaccgc				
10	<210>	54					
	<211>	250					
	<212>	DNA					
	<213>	Human					
15	<400>	54					
	catttcccca	ttggtcctga	tgttgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtggtagg	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
20	aaagggcatt	ctttaggaac	tgcatctggt	aaccacaccc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210>	55					
	<211>	2270					
25	<212>	DNA					
	<213>	Human					
	<400>	55					
30	gcgccccga	gcagcgcccg	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggcccgcgcg	ccgcccagcc	ctcgccctccc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgcacggcct	gtccgctgca	caccagcttg	ttggcgctctt	cgctcgcccg	180
	ctcgccccgg	gctaactctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctcgcc	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tgggcgctctc	cacctgcccc	gctgcctgcc	300
35	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctccg	gacggctgcg	360
	gctgctgtaa	ggctgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gccccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tccccaaaga	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtggt	660
	tcaaaagtta	cgggcagtgc	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttgcca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtctc	840
	ctgttttttg	aatggagcct	cgcacccctt	acaaggccag	aaatgtattg		900
45	ttcaaaacac	ttcatggtcc	cagtgtctca	agacctgtgg	aactgggtatc	tcacacagag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaagaaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aaagaccaaga	1080
	aatccccga	accagtcagg	tttacttacg	ctggatgttt	gagtgatgag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
50	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
	agtccctgca	atgcaactac	aactgcccgc	atgccaatga	agcagcggtt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaaa	gagtgtcaga	atcagaatca	tggagaaaaa	ggcggggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
55	ggtatttcga	aactgccaag	ggtgctggtg	cggatggaca	ctaagtcagc	cacgattgga	1560
	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcataatttc	tctaggcttt	1680
	tttctttttg	gggttctaca	gtcgtaaaag	agataataag	attagtttga	cagttttaaag	1740
	cttttattcg	tcctttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
60	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
	ggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgaataactg	gaataatttg	taaatgattt	taattttata	ttcagtgaag	agattttatt	1980
	tatggaatta	accatttaac	aaagaaatat	tacctaata	tctgagtgtg	tgccatttcg	2040
	tattttttaga	ggtgctccaa	agtcatttagg	aacaacctag	ctcacgtact	caattattca	2100
65	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
	ttataccttc	agtagagaaa	agtcttttga	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

<210> 56  
 <211> 1636  
 <212> DNA  
 5 <213> Human

<400> 56

```

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggga 60
   agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccccac 120
   cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatgggctcc 180
   tggtttgctt ggtctcaagg acactgcac gtcaaactga tcccctggcc gttggaggag 240
   cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
   cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgtggc cttcccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
   gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcatatcaa gatctgggag 480
   gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
   agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
   atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
20 gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
   tcgggtcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
   agcagtgttg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
   gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900
   acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
   tggggccctg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
   acatttttcc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
   tggacagctc ctagggtcct gtctcactg aagcacttat gccggaaaag ccttcgaagt 1200
   ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatact 1320
   cctgtcaaag ggagttgctg gaataatggg ccaaactatc ggtcttgcat tgaataagca 1380
   tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
   tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
   aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
   gacctgtgc tgcgtt

```

<210> 57  
 <211> 460  
 40 <212> DNA  
 <213> Human

<400> 57

```

45 ccattgtgtg atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
   gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
   tggaatgagc taaagcagcc gcctgggggt ggaggccgag cccatttgta tgcagcaggg 180
   ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240
   atgcccgcag agccctccct cactcccat cctgtccagc cctaattgtg caggtgggga 300
50 aactgaggct gggaagtcac atagcaagt actggcagag ctgggactgg aacccaacca 360
   gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
   ccgagctega attcgtaatc atggtcatag ctgtttcctg

```

<210> 58  
 <211> 1049  
 55 <212> DNA  
 <213> Human

<400> 58

```

60 atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60
   tgaggaccaa gatatacttt ttacagagg cacttgttcg gtctaacaca gacacctcca 120
   tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gcctggacta 180
   cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
   ggatctacaa tttttagtag tttccattg tgagtctggg tcatactttt actgcttgat 360

```

5     aaaatgtaaa cttcacctag ttcattctt ccaaatecca agatgtgacc ggaaaagtag 420  
       cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480  
       ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
       aatctttctg actggcagcc ccggtataca aatccaccaa ccaaaggacc attactgaat 600  
       ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660  
       attctggctg atgatctgtt tttccattg gagtctgaac acagtatcgt taaattgatg 720  
       tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
       aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 10     ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900  
       aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
       aaaaaccctg cagggccaaa gagcagttgc cctccagat gctttctgtg gagttctgca 1020  
       acttcaagaa agactctggc tgttctcaa

15     <210> 59  
       <211> 747  
       <212> DNA  
       <213> Human

20     <400> 59

25     tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60  
       ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
       cttaaataata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180  
       gttggttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
       atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300  
       ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360  
       aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420  
       gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
       ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 30     ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600  
       ttgaagccta ggtagggcag gatcagagat acaccctgtt ttgtctcgaa gggctccaca 660  
       gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
       cgcgaaattta gtagtaatat cggccgc